-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Article source: Medical Rubik's Cube Info
Author: Shi Bei
On December 20, Can-Fite announced that in the open-label extension trial part of the Phase II study of Namodenoson for the treatment of hepatocellular carcinoma (HCC), the last patient received the treatment achieved complete remission (CR), which means this All cancer lesions of the patient were removed
After receiving namodenson treatment, the patient has been alive for 5 years.
Namodenoson is a highly selective, oral small molecule A3 adenosine receptor (A3AR) agonist.
Can-Fite is expected to start the recruitment of Namodenoson's key Phase III trial patients in the first quarter of 2022 for the treatment of advanced HCC patients with potential Child Pugh B7 (CPB7) liver cirrhosis to support the submission of new drug applications (NDA) and Approved
It is worth noting that in August 2018, CMS reached an authorized cooperation with Can-Fite with an advance payment of US$2 million, a milestone payment of US$72.
Note: The original text has been deleted